Post Partum Depression Market Size Spurs Due To An Influx Of Pharma Companies

August 06 18:34 2020
Post Partum Depression Market Size Spurs Due To An Influx Of Pharma Companies

Post Partum Depression Market Size
The Postpartum Depression Market Size in the 7MM was estimated to be USD 138.75 Million in 2017.
The US accounted for maximum PPD Market share, with Japan occupying the second-largest shareholder of the PPD market.

DelveInsight’s ‘Postpartum Depression (PPD) – Market Insights, Epidemiology and Market Forecast – 2030 report delivers an in-depth understanding of the Postpartum Depression (PPD), historical and forecasted epidemiology as well as the Postpartum Depression (PPD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Post Partum Depression: Disease Overview

Depression is one of the most common complications of pregnancy. During or after pregnancy, women’s body undergoes several kinds of changes, including physical appearances, appetite, sleeping patterns, hormonal, and so much more. It becomes common for women to experience anxiety, mood and alterations.

Postpartum Depression is a significant form of depression that persists for more than two weeks of delivery. In rare cases, in approximately 1-2% of women (affecting 1 or 2 in 1000 women post-childbirth), Postpartum depression worsens to Postpartum psychosis within 1-2 weeks post-delivery.

Visit to learn more: https://www.delveinsight.com/blog/postpartum-depression-market/

The Postpartum Depression (PPD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Postpartum Depression (PPD) market size from 2017 to 2030. The report also covers current Postpartum Depression (PPD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Know more about the report offerings: https://www.delveinsight.com/report-store/postpartum-depression-market

Postpartum Depression Epidemiology

Postpartum depression (PPD) is the most common non-psychotic, complication of childbearing affecting approximately 10–15% of women and as such, represents a considerable public health problem affecting women and their families.

Key Highlights: Postpartum Depression Epidemiology

  • As per DelveInsight, the total diagnosed Postpartum Depression prevalent population in the 7 MM was found to be 1,134,800 in 2017, which is expected to increase further.
  • Out of all the 7MM, the US accounted for the highest Postpartum Depression prevalence, with Japan accounting for the second-highest PPD prevalence in the 7MM.
  • Among EU5 countries, France recorded the most top PPD prevalent cases with Spain accounting for the least number of cases.

Postpartum Depression Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented into:

  • Total Diagnosed Prevalent Population of Maternal Postpartum Depression
  • Type-specific Diagnosed Prevalence of Postpartum Depression scenario

Request for free sample pages: https://www.delveinsight.com/sample-request/postpartum-depression-market

Postpartum Depression Market

Postpartum Depression Market comprises of antidepressant medications, cognitive-behavioural therapy (CBT), and interpersonal therapy along with other treatments including psychodynamic therapy, light therapy, exercise, and yoga. However, the efficiency of these treatment methods remains unclear.

Key Highlights: Postpartum Depression Market

  • The Postpartum Depression Market Size in the 7MM was estimated to be USD 138.75 Million in 2017.
  • The US accounted for maximum PPD Market share, with Japan occupying the second-largest shareholder of the PPD market.

Marketed Therapies

Zulresso (brexanolone): Sage Therapeutics

Pipeline Therapies

Zuranolone (SAGE-217): Sage Therapeutics (Phase III)

Ganaxolone (CCD-1042): Marinus Pharmaceuticals (Phase II)

 

 

Scope of the Report

  • The report covers the descriptive overview of Postpartum Depression (PPD), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Postpartum Depression (PPD) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Postpartum Depression (PPD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Postpartum Depression (PPD) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Postpartum Depression (PPD) market.

 

Know more about the report offerings: https://www.delveinsight.com/report-store/postpartum-depression-market

 

Table of Contents

1 Key Insights

2 Postpartum depression (PPD) Market Overview at a Glance

3 Disease Background and Overview: Postpartum depression (PPD)

4 Epidemiology and Patient Population

5 Country-Wise Epidemiology of Postpartum Depression (PPD)

6 Treatment

7 Treatment Algorithm by American Family Physician (AFP)

8 Treatment Guidelines by Unicare

9 Treatment Guidelines by the National Institute for Health and Care Excellence (NICE)

10 Recognized Establishments

11 Unmet Needs

12 Marketed Profile

13 Postpartum Depression: 7 Major Market Analysis

14 The United States Market Outlook

15 Japan: Market Outlook

16 KOL Reviews

17 Case Reports

18 Market Drivers

19 Market Barriers

20 SWOT Analysis

21 Appendix

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Browse through our vast repository from here.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/